WntResearch is a public company listed at the Aktietorget and is a biotech company spun out of Tommy Anderssons research at Lund University, Sweden, founded in 2007.

The focus and aim of WntResearch is to develop novel anti-metastatic therapies for the treatment of cancer patients and thereby meet a large medical need. The lead project is Foxy-5 which is in clinical development for the prevention of metastases in breast, colon, and prostate cancer.